Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer

BACKGROUND: Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase ll trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone receptor positive, HER2 negative metastatic breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soohyeon, Park, Kyunghee, Kim, Gun Min, Jung, Kyung Hae, Kang, Seok Yun, Park, In Hae, Kim, Jee Hyun, Ahn, Hee Kyung, Park, Woong-Yang, Im, Seock-Ah, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819475/
https://www.ncbi.nlm.nih.gov/pubmed/35124320
http://dx.doi.org/10.1016/j.breast.2022.01.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819475/
https://www.ncbi.nlm.nih.gov/pubmed/35124320
http://dx.doi.org/10.1016/j.breast.2022.01.014

Ejemplares similares